Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

Shiragami and colleagues [1] have presented a cost-effectiveness model of the use of routine pneumococcal vaccination in infants in Japan using the 10-valent pneumococcal conjugate vaccine (PCV10) and the 13-valent pneumococcal conjugate vaccine (PCV13). In this analysis, the authors concluded that...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy 2015-06, Vol.4 (2), p.227-233
Main Authors: Farkouh, Raymond A., Hall-Murray, Cassandra, Klok, Rogier M., Hilton, Betsy, Isturiz, Raul E.
Format: Article
Language:English
Subjects:
Cost analysis
Infectious Diseases
Influenza
Internal Medicine
Letter to the Editor
Medicine
Medicine & Public Health
Pneumonia
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shiragami and colleagues [1] have presented a cost-effectiveness model of the use of routine pneumococcal vaccination in infants in Japan using the 10-valent pneumococcal conjugate vaccine (PCV10) and the 13-valent pneumococcal conjugate vaccine (PCV13). In this analysis, the authors concluded that the routine use of PCV10 was more cost-effective than PCV13. While the analysis applies modeling methodologies that are sound, many of the assumptions presented in the paper are inconsistent with current published scientic evidence, specically those regarding PCV13 effectiveness against serotype 3, PCV10 effectiveness against pneumonia, PCV10 effectiveness against otitis media, PCV10 cross-protection against serotypes not contained in the vaccine (serotypes 6 and 19A), and herd effects. We challenge these assumptions using previously conducted studies and data in the public domain.
ISSN:2193-8229
2193-6382
DOI:10.1007/s40121-015-0063-0